CONSTITUENT REPORT
Furanoeudesma-1,3-diene
Furanoeudesma-1,3-diene is one of the defining furanosesquiterpenes of true myrrh oil and one of the better documented myrrh constituents in the public literature. Live sources support strong identity and occurrence data, including repeated reports that it is a dominant component of Commiphora myrrha volatile fractions. Compared with many archive constituents, it also has a modest isolated-molecule evidence trail in anti-inflammatory cell assays, while broader analgesic discussion often comes from myrrh extracts or mixed furanodiene fractions rather than the pure constituent alone.
Chemical identity and composition
PubChem resolves furanoeudesma-1,3-diene to CID 13874240 with formula C15H18O, while NIST lists the same structure and InChIKey under CAS 115526-32-4. Trade and ACS references also circulate CAS 87605-93-4 for the same name, so public registry mapping is not fully uniform and should be treated as an alias issue rather than assumed to indicate a different chemistry. In the archive's current myrrh essential oil record, furanoeudesma-1,3-diene is the top constituent at 35.82%.
Aroma and practical use
- Use the recorded resinous, warm, dry, myrrh-like, resin descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2005 Journal of Agricultural and Food Chemistry paper quantified furanoeudesma-1,3-diene at 34.9% in supercritical CO2 myrrh extract and described hydrodistilled and steam-distilled myrrh oils as broadly similar in major composition.
A 2005 Journal of Agricultural and Food Chemistry paper quantified furanoeudesma-1,3-diene at 34.9% in supercritical CO2 myrrh extract and described hydrodistilled and steam-distilled myrrh oils as broadly similar in major composition.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2020 Molecules paper on isolated myrrh sesquiterpenes reported furanoeudesma-1,3-diene as a moderate ICAM-1 inhibitor in vitro with an IC50 of 46.3 micromolar.
A 2020 Molecules paper on isolated myrrh sesquiterpenes reported furanoeudesma-1,3-diene as a moderate ICAM-1 inhibitor in vitro with an IC50 of 46.3 micromolar.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2024 Molecules study on new myrrh sesquiterpenoids reported that furanoeudesma-1,3-diene, used as a reference substance, showed an IC50 of 46.0 micromolar in an LPS-induced nitric-oxide assay in RAW 264.7 macrophages.
A 2024 Molecules study on new myrrh sesquiterpenoids reported that furanoeudesma-1,3-diene, used as a reference substance, showed an IC50 of 46.0 micromolar in an LPS-induced nitric-oxide assay in RAW 264.7 macrophages.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2017 Biomed Research International pilot study on the standardized myrrh extract MyrLiq reported furanoeudesma-1,3-diene at 18.84 g/kg within the extract and observed pain-alleviation outcomes in volunteers, but the intervention tested the extract mixture rather than isolated furanoeudesma-1,3-diene alone.
A 2017 Biomed Research International pilot study on the standardized myrrh extract MyrLiq reported furanoeudesma-1,3-diene at 18.84 g/kg within the extract and observed pain-alleviation outcomes in volunteers, but the intervention tested the extract mixture rather than isolated furanoeudesma-1,3-diene alone.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
Within the archive's current myrrh essential oil record, furanoeudesma-1,3-diene was directly quantified at 35.82%, confirming its status as a leading chemotype marker.
Within the archive's current myrrh essential oil record, furanoeudesma-1,3-diene was directly quantified at 35.82%, confirming its status as a leading chemotype marker.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA restriction, dermal ceiling, or human tolerability study was verified for isolated furanoeudesma-1,3-diene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the human analgesic evidence located involved a standardized myrrh extract rather than purified furanoeudesma-1,3-diene, archive copy should avoid direct pain-relief claims for the isolated molecule.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
LindestreneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Lindestrene report →How the effects were investigated
icam 1 inhibition in vitro
A 2020 myrrh sesquiterpene paper reported furanoeudesma-1,3-diene as a moderate inhibitor of ICAM-1 in vitro, offering a plausible cell-adhesion-related anti-inflammatory mechanism at the laboratory level.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
no suppression in lps no assay reference compound
A 2024 follow-up study used furanoeudesma-1,3-diene as a reference substance in an LPS-induced nitric oxide assay and reported an IC50 of 46.0 micromolar, placing it within a moderate in vitro anti-inflammatory signal rather than a highly potent benchmark.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Public CAS mapping is inconsistent, with high-credibility sources using both 115526-32-4 and 87605-93-4 for this name.
- The constituent-specific activity evidence is still limited to in vitro assays, while the human evidence found was extract-level rather than isolated-molecule testing.
- Constituent-specific dermal, inhalation, reproductive, and chronic safety data were not verified in this pass.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.